1CG trade ideas
#CRSP $CRSP easy follow the buy sell why not to double check for assured profit before you pay a dime
Easy line to follow and simple chart be your guide here , it works for a week in #trade
Long (potential takeover, solid pipeline, tons of cash)- potential aim for takover (I suppose by VRTX ) . Company has 2.5B in cash, no debt with market cap about 4.5B$ (EV = 2.0 B)
- solid pipeline and probably will be first who get FDA approval for commercial CRISPR product
- got most of up front payment for milestones in CRISPR among competitors ( about 1b$ from Vertex and collaboration with Bayer). BEAM for example got only 300m$ in up front payment, NTLA even less.
That means CRSP has enough cash for 4 years R&D without share offering and sustain global recession.
No brainer alpha at a cheap price1) Crisper has a lot of cash on hand to survive through tightening of QE and fund pipeline without dilution
2) Potential takeover by $VRTX or other compamy at current prices VERY possible.
Bullish Gartley with Bullish Divergence Visible on the WeeklyWe have Classic Divergence on the MACD and Hidden Bullish Divergence on the RSI visible on the Weekly chart at the PCZ of a Bullish Gartley.
CRISPR- The future of medicine?I would buy 40% at this price
then if the price drops to $30-40 I'd buy the rest of the 60%
crispr call..aejfj;agiojagwejga ldak;jjewjg ag akgje;aijgwei vaie;jgijewpogjpwaeg wamaj;wefj pij;aewpfjoefj
$crsp - consolidation continues...I expect this to consolidate for the next few weeks.. probably into Q1/Q2 2022... leading to an eventual breakout to retest ATH
CRISPR Therapeutic needs to break 83.46. This is a critical testCrispr has been moving up since the Morning star break out on 13th December. Its further progress hinges on breaking the 83.46 resistance. It has tried piercing this resistance twice but failed. The resistance line at 83.46 and the upward support channel formed since 14th December at $70.37 is intersecting 83.46 on 28th December and CRSP has to break out before that to make any further progress. Option strategies can be deployed to exploit the opportunity either way.
nice downtrend break here! looking for a rally now 🍿fresh breakout past a 5 month downtrend on CRSP ! if it holds and doesn't break back into the trend potential price targets for early 2022 area 98.31-113.89-129.47
like and follow for more 💘
CRSPCRSP It's time to update the idea. The care turned out to be very deep, although this option of leaving for zone 77 was supposed. Now we have dropped out of the channel a little, we will count for an error, we are also holding on to the ema200 during the week, we have formed hidden divergences during the week, taking into account the potential of the company, the growth of xbi and the VRTX partner may be interesting.
It may still come down and test the "trend", but we are already at a good level
50sma is the next resistanceBroke through the yellow downward trendline today with volume. The 50sma coincides with my gray trendline. Big upside if it can break through that.
Time to buy CRSPCatalysts coming in 2022 and weekly trend changes based on heiken ashii candles, plus the bounce at 74+- which was prior resistance, plus analyst ratings make this an attractive buy for me at these levels.
CRSP on a major weekly level. What's coming next? Today we will take a look at CRISPR Therapeutics.
Which are the main technical elements we can see here?
a) The price is against a major Support/Resistance level, working since 2018. The price reaction on these zones tends to provide solid insight into future movements.
b) Let's assume the price bounces on the current zone; what can we expect?
- A movement towards the descending trendline around 100.00. IF that happens, that would be a take-profit level for me. Why? Because we tend to observe corrections once the price reaches a major level. You don't want to be insight a sideways movement for 100 days
c) Let's assume that the price breaks the current level and keeps falling. What can we expect?
- A movement towards the ascending trendline around 50.00. That would be the next level where I would start thinking again about bullish reversals.
d) I'm a position trader. What is the most relevant level right now to develop setups?
-If that's your case, I want to see first a breakout of the descending trendline; IF that happens, I want to see a correction of around 50 days. IF that is the case, I will be interested in trading that breakout for the long term. However, at the moment, we are far away from that situation, and I would stay away from this chart for long-term setups.
Thanks for reading! Feel free to share your view of this in the comments.
CRISPR BUY OR NOT TO BUY..?Third Quarter 2021 Financial Results
• Cash Position: Cash, cash equivalents, and marketable securities were $2,477.4 million as of
September 30, 2021, compared to $2,589.4 million as of June 30, 2021. The decrease in cash of
$112.0 million was primarily driven by cash used in operating activities to support ongoing
research and development of the Company’s clinical and pre-clinical programs.
• Revenue: Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to
$0.1 million for the third quarter of 2020. Collaboration revenue primarily consisted of revenue
recognized in connection with our collaboration agreements with Vertex.
• R&D Expenses: R&D expenses were $105.3 million for the third quarter of 2021, compared to
$71.0 million for the third quarter of 2020. The increase in expense was driven by the development
activities supporting the advancement of the hemoglobinopathies program and wholly-owned
immuno-oncology programs, as well as increased headcount and supporting facilities, related
expenses.
• G&A Expenses: General and administrative expenses were $24.4 million for the third quarter of
2021, compared to $21.5 million for the third quarter of 2020. The increase in general and
administrative expenses for the year was primarily driven by headcount-related expenses.
• Net Loss: Net loss was $127.2 million for the third quarter of 2021, compared to a net loss of
$92.4 million for the third quarter of 2020.
crisprtx.gcs-web.com
MACD: BEARISH CROSS
RSI: OVERSOLD
VOLUME: LOW
CURRENT SUPPORT @ 1.272 FIB
1.618 IS YOUR IMPULSE TARGET FOR A BREAK IN EITHER DIRECTION
Puzzled on this one honestly, looks like it wants to go lower, but we'll see at the weekly close. Keep an eye on the SPY index.
DYOR
PRACTICE RISK MANAGEMENT
GOOD LUCK
Return to the mean-Covid ignored. We returned to the mean.
-Purple area = consolidation zone = buy zone.
CRISPR is a truely amazing discovery. Imagine if we could perfectly edit genes within 5 or 10 years. I don't think everyone understands how big this is. Good luck! Target 1 = double top, other 2 the fibonacci extensions.
Edit: Don't buy before we stay above the 20MA.
CRSP Possible BottomCRSP is currently at key support and the 200 week moving average. This may be a possible bottom, however it is best to look for an entry on a lower time frame (4hr or 1hr chart) before entering. Bottoming patterns to look out for are inverted head and shoulders, double bottoms, and/or higher highs with higher lows.
CRSP - WEDGE ON SUPPORT - PIVOT CANDLE CONFORMATION **ON ALERT**All,
Pretty easy to see why you would be bullish here. Few things need to happen.
1) full candle break watch for a gap etc
2) needs to break horizontal SR at 81.50s (full candle above)
3) market needs to hold this in here if it were to somehow lose these yellow levels would be big downside imo.
Add alerts and keep this on a short timeline maybe literally one more day.
CRSP: 45, then LongThat was a nasty double top on the monthly time frame.weve come this far and we are over sold but we may come all the way down to the main support. Comforting as well to see volume increasing and picking up again recently.
Over sold on multiple indicatora.
Not trading advice.
